Amarin : January 2022 Investor Deck

a new paradigm in preventative cardiovascular care

Investor Presentation

JANUARY 2022

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon

or refer to future events or conditions, including financial guidance and milestones. These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

This presentation is intended for communication with investors and not for drug promotion.

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

AMARIN

2

A

VISION...

...to stop heart disease from being a leading cause of death

For 30 years, the focus has been on lowering LDL cholesterol. Statins have reduced LDL with success and still serve a critical purpose, but they are not the complete solution. Elevated triglycerides are also an important marker to identify cardiovascular risk.

Now is the time to Act on CVD

3

Cardiovascular Disease (CVD) Is an Enormous and Worsening Public Health Burden

US CVD BURDEN

On average someone dies of CVD

EVERY 36 SECONDS

in the US1

$1.1tn

Estimated economic burden by 20352

44M patients

Are projected to be on statins3

Leading cause of death globally

EUROPE CVD BURDEN

~60M

with CVD in Europe4

€210BN

annual spending on CV disease management4

>4M

People die each year from CVD in the European WHO region5

Increasing prevalence

INTERNATIONAL CVD BURDEN

523M

living with CVD globally6

~18M CVD deaths

globally in 20196

China alone

290M WITH CVD

and the leading cause of death7

High and increasing

economic burden

AMARIN	1 Heart Disease and Stroke Statistics-2021Update; ACC2 Cardiovascular Disease: A Costly Burden for America Projections Through 2035; 3 IQVIA, Total Patient Tracker, Statin Projected Patient Counts (USC 32110 HMG-	4
COA REDUCTASE INHIB) 12-months ending November 2021, accessed 1/7/2022; 4 European Heart Network A Blue Print for Action on CVD 20205 ESC: Cardiovascular Disease Statistics 2019	6 Global Burden of
Cardiovascular Diseases and Risk Factors, 1990-20197 China Cardiovascular Diseases Report 2018: An Updated Summary

Lowering LDL-C Helps But is Not Enough for Many Patients

Controlled LDL-C doesn't eliminate CV risk; P-CVR often remains; 25%- 35% lowering major adverse CV events (MACE) shown in CV outcome studies of statin therapies.

P-CVR - Persistent Cardiovascular Risk

Placebo groups from multiple recent trials show high P-CVR despite statin- based standard-of-care; 14.6% to 34.7% of patients treated for LDL-C, but not for P-CVR, experienced a major adverse cardiovascular event (MACE) in 3-7 Years.

LDL-C control

25-35%

Persistent risk beyond LDL-C

Patients with an event, %*

30

20

10

IMPROVE-IT: 34.7% of statin-treatedpatients had

a MACE at

7 years3

REDUCE-IT®: 28.3%

of statin-treated

patients had

a MACE at

5 years2

FOURIER: 14.6% of statin-treatedpatients had a MACE at 3 years1

All statin-treated patients

had well controlledLDL-Clevels (rangingfrom 67-92mg/dL*)

control 65-75%

0

Years of follow up

357

Cross-trial comparisons are subject to differences in populations,

primary outcomes, and other trial design aspects

	Note: FOURIER, REDUCE-IT® and IMPROVE-IT trials evaluated evolocumab, icosapent ethyl and ezetimibe / simvastatin, respectively
AMARIN	* 67 mg/dL is equivalent to 0.8 mmol/L and 92 mg/dL is equivalent to 1.0 mmol/L	5
1. Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722; 2. Bhatt DL, et al; for REDUCE-IT® Investigators. N Engl J Med. 2019;380(1):11-22; 3. Cannon CP, et al. N Engl J Med. 2015;372(25):2387-2397